Latest filing published 21 Jul 2025 for Blueprint Medicines Corp. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
All filings by Christina Rossi on record concern Blueprint Medicines Corp, in the capacity of senior executive. The record holds 20 filings, for trades running from 3 November 2021 to 17 July 2025.
Sales make up the whole of the open-market record (14 sales, €2.4M). Other entries cover 6 share grants. Since January 2025: no purchases and 7 sales on the market.
The newest entry dates from 21 July 2025: a share grant, in Blueprint Medicines Corp. Filings reach the SEC (Form 4) feed a median of 4 days after the trade. US insiders must file a Form 4 within two business days of a trade. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
20 of 20 declarations